<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04564066</url>
  </required_header>
  <id_info>
    <org_study_id>ARGX-113-1907</org_study_id>
    <nct_id>NCT04564066</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Multiple Intravenous Infusions of Efgartigimod With Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>argenx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>argenx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the pharmacodynamics, pharmacokinetics and safety of efgartigimod as&#xD;
      an intravenous infusion with efgartigimod as a subcutaneous injection in healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 18, 2020</start_date>
  <completion_date type="Actual">February 11, 2021</completion_date>
  <primary_completion_date type="Actual">December 24, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage reduction in total IgG levels, compared to baseline, at day 29 (week 4), 7 days after the fourth IV or SC administration of efgartigimod</measure>
    <time_frame>After four weeks (day 29)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage reduction in total IgG levels at all other assessment timepoints as of week 4</measure>
    <time_frame>Up to 15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage reduction in levels of IgG subtypes (IgG1, IgG2, IgG3, and IgG4) at all assessment timepoints</measure>
    <time_frame>Up to 15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes from baseline in total IgG levels at all assessment timepoints</measure>
    <time_frame>Up to 15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes from baseline in levels of IgG subtypes (IgG1, IgG2, IgG3, and IgG4) at all assessment timepoints</measure>
    <time_frame>Up to 15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUEC for percentage reduction in total IgG levels per weekly interval after each dose (week 1, week 2, week 3, and week 4), over the interval week 1 to week 4, and over the entire study period (week 1 to week 11)</measure>
    <time_frame>Up to 11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUEC for percentage reduction in IgG levels for each subtype per weekly interval after each dose (week 1, week 2, week 3, and week 4), over the interval week 1 to week 4, and over the entire study period (week 1 to week 11)</measure>
    <time_frame>Up to 11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of efgartigimod and derived PK parameters</measure>
    <time_frame>Up to 15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of efgartigimod</measure>
    <time_frame>Up to 15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough of efgartigimod</measure>
    <time_frame>Up to 15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte count</measure>
    <time_frame>Up to 15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil count</measure>
    <time_frame>Up to 15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocyte count</measure>
    <time_frame>Up to 15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital sign measurement: blood pressure</measure>
    <time_frame>Up to 15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital sign measurement: heart rate</measure>
    <time_frame>Up to 15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG recording of QTcF</measure>
    <time_frame>Up to 15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and characterization of TEAEs</measure>
    <time_frame>Up to 15 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>efgartigimod IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous infusions of efgartigimod</description>
  </arm_group>
  <arm_group>
    <arm_group_label>efgartigimod PH20 SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subcutaneous injections of efgartigimod PH20 SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>efgartigimod IV</intervention_name>
    <description>intravenous infusions of efgartigimod</description>
    <arm_group_label>efgartigimod IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>efgartigimod PH20 SC</intervention_name>
    <description>subcutaneous injections of efgartigimod PH20 SC</description>
    <arm_group_label>efgartigimod PH20 SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject is between 18 and 65 years of age, inclusive, on the day when the ICF is&#xD;
             signed.&#xD;
&#xD;
          2. The subject is either male or female of non-childbearing potential (postmenopausal&#xD;
             [defined by continuous amenorrhea for at least 1 year without an alternative medical&#xD;
             cause with a follicle-stimulating hormone (FSH) of &gt;33.4 IU/L; in subjects on hormonal&#xD;
             replacement therapy, a historical value pretreatment of &gt;33.4 IU/L will be accepted as&#xD;
             proof of menopausal status]) OR have a documented permanent sterilization procedure&#xD;
             (ie, hysterectomy, bilateral salpingectomy, and bilateral oophorectomy).&#xD;
&#xD;
          3. The female subject has a negative pregnancy test at day -1&#xD;
&#xD;
          4. The subject has a body mass index (BMI) between 18 and 30 kg/m2, inclusively, with a&#xD;
             weight of ≥50 kg and ≤100 kg at screening.&#xD;
&#xD;
          5. The subject is able to understand the requirements of the study, provide written&#xD;
             informed consent (including consent for the use and disclosure of research-related&#xD;
             health information), willing and able to comply with the protocol procedures&#xD;
             (including required study visits).&#xD;
&#xD;
          6. The subject is in good physical and mental health, per the opinion of the&#xD;
             investigator, based on medical history, physical examination, ECG, and vital sign&#xD;
             findings; and biochemistry, hematology, virology, and urinalysis test results prior to&#xD;
             the first IMP administration.&#xD;
&#xD;
          7. The non-sterilized male subject who is sexually active with a female partner of&#xD;
             childbearing potential must use effective contraception (failure rate of &lt;1% per&#xD;
             year). Male subject practicing true sexual abstinence (when consistent with the&#xD;
             preferred and usual life style of the participant) can be included. The sterilized&#xD;
             male subject who has had a vasectomy with documented aspermia postprocedure can be&#xD;
             included. In addition, no male subject will be allowed to donate sperm during the&#xD;
             period from signing the ICF, throughout the duration of the trial, and 90 days after&#xD;
             the last administration of the IMP.&#xD;
&#xD;
          8. The condition of the skin tissue on the subject's abdomen must allow for absorption&#xD;
             and assessment of local safety of the planned SC injection, as determined by the&#xD;
             investigator.&#xD;
&#xD;
          9. The subject agrees to discontinue and refrain from all medications (including&#xD;
             over-the-counter and/or prescription medications), except for occasional paracetamol&#xD;
             use (maximum dose of 2 g/day and maximum of 10 g/2 weeks), antacid use, and ibuprofen&#xD;
             use (maximum dose of 400 mg/day and not to be coadministered with antacid), at least 2&#xD;
             weeks before the first IMP administration through the final follow-up visit on day 78.&#xD;
&#xD;
         10. The subject agrees to withhold from strenuous activities from at least 2 weeks before&#xD;
             the first IMP administration through the final follow-up visit on day 78.&#xD;
&#xD;
         11. The subject is a non-smoker and does not use any nicotine-containing products. A&#xD;
             non-smoker is defined as an individual who has abstained from smoking for at least 1&#xD;
             year prior to screening.&#xD;
&#xD;
         12. The subject has a negative nicotine analyte test at screening and on day -1.&#xD;
&#xD;
         13. The subject has a negative urine drug screen (amphetamines, barbiturates,&#xD;
             benzodiazepines, cannabis, cocaine, opiates, methadone, and tricyclic antidepressants)&#xD;
             at screening and on day -1.&#xD;
&#xD;
         14. The subject has a negative alcohol urine test at screening and on day -1.&#xD;
&#xD;
         15. The subject has a body temperature of 35.2°C to 37.6 °C at screening and on day -1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subject has previously participated in clinical studies with efgartigimod&#xD;
             (ARGX-113) and was administered an IMP.&#xD;
&#xD;
          2. The subject has a known hypersensitivity to 1 of the components in the IMP, or a&#xD;
             history of severe allergic or anaphylactic reactions, in the opinion of the&#xD;
             investigator.&#xD;
&#xD;
          3. The subject tests positively at screening for any of the following conditions: a. The&#xD;
             subject has an active hepatitis B infection (acute or chronic) at screening as&#xD;
             determined by hepatitis B serology.&#xD;
&#xD;
             b. The subject has serology positive for hepatitis C virus antibody (HCV Ab). c. The&#xD;
             subject has human immunodeficiency virus (HIV) positive serology.&#xD;
&#xD;
          4. Subjects with clinically significant active or chronic uncontrolled bacterial, viral,&#xD;
             or fungal infection at screening.&#xD;
&#xD;
          5. Subjects with clinical evidence of other significant serious diseases, subjects who&#xD;
             underwent a recent major surgery, or any other reason which could confound the results&#xD;
             of the trial or put the subject at undue risk.&#xD;
&#xD;
          6. The subject has total IgG &lt;6 g/L at screening.&#xD;
&#xD;
          7. The subject has presence or sequelae of gastrointestinal, liver, kidney, or any other&#xD;
             condition known to potentially interfere with the absorption, distribution,&#xD;
             metabolism, or excretion of IMP.&#xD;
&#xD;
          8. The subject has a history of malignancy unless deemed cured by adequate treatment with&#xD;
             no evidence of recurrence for ≥3 years before first IMP administration. Subjects with&#xD;
             the following cancer can be included anytime:&#xD;
&#xD;
               1. Adequately treated basal cell or squamous cell skin cancer&#xD;
&#xD;
               2. Carcinoma in situ of the cervix&#xD;
&#xD;
               3. Carcinoma in situ of the breast or&#xD;
&#xD;
               4. Incidental histological finding of prostate cancer (TNM stage T1a or T1b)&#xD;
&#xD;
          9. The subject has a clinically relevant abnormality detected on ECG recording regarding&#xD;
             either rhythm or conduction (eg, QTcF &gt;450 ms for male and QTcF &gt;470 ms for female&#xD;
             subjects, or a known long QT syndrome). A first-degree heart block or sinus arrhythmia&#xD;
             will not be considered a significant abnormality.&#xD;
&#xD;
         10. The subject has clinically relevant abnormalities detected in vital sign measurements&#xD;
             prior to dosing.&#xD;
&#xD;
         11. The subject has significant blood loss (including blood donation &gt;500 mL) or has had a&#xD;
             transfusion of any blood product within 12 weeks prior to the (first) IMP&#xD;
             administration or a scheduled transfusion within 4 weeks after the end of the study.&#xD;
&#xD;
         12. The subject has been treated with any drug known to have a well-defined potential for&#xD;
             toxicity to a major organ in the last 3 months preceding the initial IMP&#xD;
             administration.&#xD;
&#xD;
         13. The subject has a history of consuming more than 21 units of alcoholic beverages per&#xD;
             week or a history of alcoholism or drug/chemical/substance abuse within 2 years prior&#xD;
             to screening (Note: 1 unit = 330 mL of beer, 110 mL of wine or 28 mL of spirits).&#xD;
             Regular consumption of a large quantity of coffee, tea ( &gt;6 cups per day), or&#xD;
             equivalent within 3 weeks prior to first dose is also exclusionary.&#xD;
&#xD;
         14. The subject has received investigational drug within 3 months or 5 half-lives of the&#xD;
             drug (whichever is longer) prior to first IMP administration.&#xD;
&#xD;
         15. The subject has received a vaccination (eg, influenza vaccine) within the last 4 weeks&#xD;
             prior to screening.&#xD;
&#xD;
         16. The subject has received any systemic immunosuppressant agent within 6 months prior to&#xD;
             the initial IMP administration.&#xD;
&#xD;
         17. The subject has received any systemic steroid within 3 months prior to the initial IMP&#xD;
             administration.&#xD;
&#xD;
         18. The subject has received any monoclonal antibody, within 6 months prior to first IMP&#xD;
             administration.&#xD;
&#xD;
         19. The subject is an employee of the investigator or study center, with direct&#xD;
             involvement in the proposed study or other studies under the direction of that&#xD;
             investigator or study center, as well as a family member of an employee or the&#xD;
             investigator.&#xD;
&#xD;
         20. The subject has any condition or circumstances that in the opinion of the investigator&#xD;
             may make a subject unlikely or unable to complete the study or comply with study&#xD;
             procedures and requirements.&#xD;
&#xD;
         21. The subject has any condition impairing phlebotomy.&#xD;
&#xD;
         22. The subject is a pregnant or lactating women or intending to become pregnant during&#xD;
             the study or within 90 days after last dosing.&#xD;
&#xD;
         23. The subject has a positive nasopharyngeal PCR test for SARS-CoV-2 on days -2 or -1.&#xD;
             24. The subject has had any contact with SARS-CoV-2 positive or COVID-19 patients&#xD;
             within the last 2 weeks prior to admission to the clinical research center.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Study Site 1</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 11, 2020</study_first_submitted>
  <study_first_submitted_qc>September 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

